Form 7 Monthly Progress Report April 2023
Form 7 Monthly Progress Report March 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 May 2, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
Press Release – BIOMARK LATEST RESULTS ACCEPTED FOR PRESENTATION AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING 2023
BIOMARK LATEST RESULTS ACCEPTED FOR PRESENTATION at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 New analyses from a large retrospective validation study of early lung cancer metabolomics panel, underscoring strength of BioMark’s liquid biopsy platform, to be presented. Vancouver, British Columbia – (May 3rd, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) […]
Form 7 Monthly Progress Report March 2023
Form 7 Monthly Progress Report March 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 April 2, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
BIOMARK PRESENTS NOVEL LIQUID BIOPSY DATA IN PULMONARY NEUROENDOCRINE TUMORS
BIOMARK PRESENTS NOVEL LIQUID BIOPSY DATA IN PULMONARY NEUROENDOCRINE TUMORS Vancouver, British Columbia – (March 16th, 2023) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that novel liquid biopsy data presented this […]
Indigenous Innovator: Dr. Nadine Caron’s Quest for Equity in Cancer Care and Research
Indigenous Innovator: Dr. Nadine Caron’s Quest for Equity in Cancer Care and Research Written by Tom Raycove, CEO Disrupted Logic Interactive Inc. Black History Month and Its Role in Understanding the Experiences of Indigenous Peoples Black History Month is a time to celebrate the contributions and achievements of black people, but it is also an […]
BIOMARK PROVIDES THIRD QUARTER OPERATIONAL UPDATE AND 2023
BIOMARK PROVIDES THIRD QUARTER OPERATIONAL UPDATE AND 2023 Vancouver, British Columbia – (March 1st, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers reported its operational update for the third quarter ended December […]
Form 7 Monthly Progress Report February 2023
Form 7 Monthly Progress Report February 2023 Name of Listed Issuer: Trading Symbol: Number of Outstanding Listed Securities: Date: BioMark Diagnostics Inc. (the “Issuer”) BUX 83,286,229 March 2, 2023 This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to […]
Revolutionizing Cancer Research: Meet Dr. Juliet Daniel, the Trailblazing Black Scientist Making a Difference in the Lives of Triple Negative Breast Cancer (TNBC) Patients
Revolutionizing Cancer Research: Meet Dr. Juliet Daniel, the Trailblazing Black Scientist Making a Difference in the Lives of Triple Negative Breast Cancer (TNBC) Patients Written by Tom Raycove, CEO Disrupted Logic Interactive Inc. Celebrating Black History Month, we shine a spotlight on Dr. Juliet Daniel, a trailblazer in the field of cancer research. Driven by […]
Breaking Barriers – Past and Current: Celebrating the Legacy of Dr. Clarice Reid, Pioneer in Sickle Cell Research, Biomark Diagnostics
Breaking Barriers Past: Celebrating the Legacy of Dr. Clarice Reid, Pioneer in Sickle Cell Research Current: BioMark Diagnostics Inc. Pioneering Early Stage Cancer Detection Written by Tom Raycove, CEO Disrupted Logic Interactive Inc. Dr. Clarice Reid: Pioneering Work in the Field of Sickle Cell Disease Dr. Clarice Reid was a trailblazer in the field of […]
BioMark Receives Funding, Support, Research and Development Project for Cancer Treatment Monitoring
BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce today that […]
